Impact of modified WuMei decoction combined with Bifidobacterium triple viable enteric-coated capsules on clinical efficacy and intestinal microbiota in patients after endoscopic resection of colonic polyps.

BACKGROUND AND STUDY AIMS: This work was designed to assess the impact of modified WuMei decoction (MWMD) combined with Bifidobacterium triple viable (BTV) enteric-coated capsules on patients following endoscopic resection of colonic polyps.

PATIENTS AND METHODS: This study enrolled 80 patients with colonic polyps and divided them into a control group and an observation group. Both groups underwent endoscopic polypectomy. The control group received BTV enteric-coated capsules, while the observation group received both BTV enteric-coated capsules and MWMD. Baseline characteristics, postoperative recurrence rates, clinical efficacy, traditional Chinese medicine (TCM) syndrome scores, intestinal microbiota, serum inflammatory cytokines, gastrointestinal quality of life index (GLQI), intestinal mucosa repair, and postoperative complications were compared.

RESULTS: Baseline characteristics were similar between the two groups (P > 0.05). At 12 months postoperatively, the observation group demonstrated a lower recurrence rate (P < 0.01) and superior clinical outcomes (P < 0.01). After treatment, TCM symptom scores in this group showed significant improvement (P < 0.05), with a notable reduction in Escherichia coli levels (P < 0.01) and a substantial increase in Bifidobacterium and Lactobacillus counts (P < 0.01). The observation group also exhibited higher GLQI scores (P < 0.01), substantially reduced serum inflammatory markers (P < 0.05, P < 0.01), better intestinal mucosal healing (P < 0.01), and a lower incidence of postoperative complications (P < 0.05).

CONCLUSION: The combination of MWMD and BTV demonstrated good clinical efficacy in patients undergoing endoscopic resection of colonic polyps, promoting intestinal mucosal repair and reducing postoperative complications.